The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

This is a multi-center, open-label, non-randomized proof-of-concept trial. Two cooperating HIV-specialized centres represented by Dr. med. Hans Jaeger and Prof. Dr. Johannes Bogner are planning to perform an IIT (investigator initiated trial) with the goal to eradicate HIV in N=40 HIV-infected patients with either primary infection or chronic infection and successful HAART (Highly Active Antiretroviral Treatment) of several years.

All patients will be started on a multi-drug HAART including two Nucleoside-Reverse-Transcriptase-Inhibitors (NRTI´s), one Protease-Inhibitor (PI), a CCR5-inhibitor and an Integrase-Inhibitor (INI). Decay of viral reservoirs like latently HIV-infected CD4+ T-cells will be monitored over time.

Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also "Eligibility") intensified by Maraviroc + Raltegravir

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 70 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

For all patients:

HIV-infected patient

Age greater 18 years

No acute AIDS-defining disease or history of AIDS- defining disease

CD4-cell nadir above or equal 200 cells/µL

Hemoglobin greater 8 g/dl

Neutrophil count greater 750 cells/µL

Platelet count greater 50.000 cells/µL

AST/ALT below 5x upper limit of normal range

No evidence for drug intolerability

No prior use of an HIV integrase inhibitor or CCR5 antagonist

No presence of malignancy (requiring active treatment and malignancy within 5 years prior to enrolment (even if in complete remission)

No significant underlying disease (non-HIV) that might impinge upon disease progression or death

No history of alcohol or other substance abuse or other condition which in the opinion of the investigator would interfere with the patient compliance or safety.

Written informed consent

For males and premenopausal females use of acceptable methods of birth control during the entire study and for 6 weeks thereafter

ELISA positive or negative and Western Blot negative or positive with less or equal 2 bands at screening visit

No primary resistance to PI´s and NRTI´s

CCR5-tropic virus

Exclusion criteria:

Evidence for drug intolerability or contraindication concerning any drug foreseen for MDC HAART

Documented HIV-1 resistance to PI and/or NRTI.

CD4 nadir <200/µL

Acute AIDS-defining disease or history of AIDS-defining disease

CHI: preceding virological failure

History of alcohol or other substance abuse or other condition which in the opinion of the investigator would interfere with the patient compliance or safety.

Any of the following abnormal laboratory test results in screening:

Hemoglobin < 8 g/dL

Neutrophil count < 750 cells/µL

Platelet count < 50,000 cells/µL

AST or ALT > 5x the upper limit of normal

Presence of malignancy (requiring active treatment and malignancy within 5 years prior to enrolment (even if in complete remission)

Significant underlying disease (non-HIV) that might impinge upon disease progression or death

Prior use of any experimental HIV- Integrase-Inhibitor or CCR5-antagonist.

Patient is pregnant or breastfeeding, or expecting to conceive (within the duration of the study). Patient is expecting to donate eggs (within the duration of the study). Patient is expecting to donate sperm (within the duration of the study).

Contraindications for Maraviroc (Celsentri®) or Raltegravir (Isentress®) according to the respective summary of product characteristics (see also product informations attached to the protocol) (Hypersensitivity to the active substances or any of the excipients).